Travere Therapeutics (TVTX) Stock Forecast & Price Target

Compare

583 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TVTX Analyst Ratings

Strong Buy

12 Buy

2 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Travere

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TVTX Stock 12 Month Forecast

Average Price Target

$42.73

▲(40.60% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Travere Therapeutics in the last 3 months. The average price target is $42.73 with a high forecast of $49.00 and a low forecast of $31.00. The average price target represents a 40.60% change from the last price of $30.39.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","50":"$50","22.25":"$22.3","31.5":"$31.5","40.75":"$40.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$49.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.72727272727273,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$31.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,22.25,31.5,40.75,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.095,34.318461538461534,35.54192307692308,36.76538461538461,37.988846153846154,39.21230769230769,40.43576923076923,41.65923076923077,42.88269230769231,44.106153846153845,45.32961538461539,46.55307692307692,47.776538461538465,{"y":49,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.095,33.835944055944054,34.57688811188811,35.317832167832165,36.05877622377622,36.799720279720276,37.54066433566433,38.28160839160839,39.02255244755245,39.763496503496505,40.50444055944056,41.245384615384616,41.98632867132867,{"y":42.72727272727273,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.095,32.933846153846154,32.77269230769231,32.61153846153846,32.450384615384614,32.28923076923077,32.128076923076925,31.966923076923077,31.80576923076923,31.644615384615385,31.483461538461537,31.322307692307692,31.161153846153844,{"y":31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.44,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.52,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.19,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.21,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.095,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$49.00

Average Price Target$42.73

Lowest Price Target$31.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

02/23/26

Analysts Are Bullish on These Healthcare Stocks: MiMedx Group (MDXG), Ufp Technologies (UFPT)

Edward Nash

Canaccord Genuity

$47

Buy

54.66%

Upside

Reiterated

02/23/26

Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM)

Alex Thompson CFA

Stifel Nicolaus

$31

Hold

2.01%

Upside

Reiterated

02/20/26

Analysts Conflicted on These Healthcare Names: US Physical Therapy (NYSE: USPH), Travere Therapeutics (NASDAQ: TVTX) and Praxis Precision Medicines (NASDAQ: PRAX)

Tyler Van Buren

TD Cowen

$40→$45

Buy

48.08%

Upside

Reiterated

02/20/26

Analysts Offer Insights on Healthcare Companies: Integra Lifesciences (NASDAQ: IART) and Travere Therapeutics (NASDAQ: TVTX)

Jason Zemansky

Bank of America Securities

$44

Buy

44.78%

Upside

Reiterated

02/20/26

Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

Laura Chico

Wedbush

$37→$39

Buy

28.33%

Upside

Reiterated

02/20/26

Wedbush Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

Joseph Pantginis

H.C. Wainwright

$47

Buy

54.66%

Upside

Reiterated

02/20/26

H.C. Wainwright Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

02/20/26

Analysts Offer Insights on Healthcare Companies: Butterfly Network (NYSE: BFLY), UnitedHealth (NYSE: UNH) and Travere Therapeutics (NASDAQ: TVTX)

Yigal Nochomovitz

Citi

$48

Buy

57.95%

Upside

Reiterated

02/20/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bicara Therapeutics Inc. (NASDAQ: BCAX), Accendra Health (NYSE: ACH) and Travere Therapeutics (NASDAQ: TVTX)

Vamil Divan

Guggenheim

$49

Buy

61.24%

Upside

Reiterated

02/11/26

Guggenheim Keeps Their Buy Rating on Travere Therapeutics (TVTX)

Allison Bratzel

Piper Sandler

$35→$38

Hold

25.04%

Upside

Reiterated

02/06/26

Travere Therapeutics price target raised to $38 from $35 at Piper SandlerTravere Therapeutics price target raised to $38 from $35 at Piper Sandler

Joseph Schwartz

Leerink Partners

―

Buy

―

Reiterated

01/13/26

Leerink says Travere's Filspari PDUFA extension removes worst case scenario Leerink says Travere's Filspari PDUFA extension removes worst case scenario

Gavin Clark-Gartner

Evercore ISI

$42

Buy

38.20%

Upside

Reiterated

01/13/26

Evercore ISI Remains a Buy on Travere Therapeutics (TVTX)

Mohit Bansal

Wells Fargo

$40

Buy

31.62%

Upside

Reiterated

01/13/26

Wells Fargo Remains a Buy on Travere Therapeutics (TVTX)

Maury Raycroft

Jefferies

$35

Buy

15.17%

Upside

Reiterated

09/10/25

AdCom cancellation 'clear positive' for Travere Therapeutics, says JefferiesAdCom cancellation 'clear positive' for Travere Therapeutics, says Jefferies

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

02/23/26

Analysts Are Bullish on These Healthcare Stocks: MiMedx Group (MDXG), Ufp Technologies (UFPT)

Edward Nash

Canaccord Genuity

$47

Buy

54.66%

Upside

Reiterated

02/23/26

Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM)

Alex Thompson CFA

Stifel Nicolaus

$31

Hold

2.01%

Upside

Reiterated

02/20/26

Analysts Conflicted on These Healthcare Names: US Physical Therapy (NYSE: USPH), Travere Therapeutics (NASDAQ: TVTX) and Praxis Precision Medicines (NASDAQ: PRAX)

Tyler Van Buren

TD Cowen

$40→$45

Buy

48.08%

Upside

Reiterated

02/20/26

Analysts Offer Insights on Healthcare Companies: Integra Lifesciences (NASDAQ: IART) and Travere Therapeutics (NASDAQ: TVTX)

Jason Zemansky

Bank of America Securities

$44

Buy

44.78%

Upside

Reiterated

02/20/26

Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

Laura Chico

Wedbush

$37→$39

Buy

28.33%

Upside

Reiterated

02/20/26

Wedbush Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

Joseph Pantginis

H.C. Wainwright

$47

Buy

54.66%

Upside

Reiterated

02/20/26

H.C. Wainwright Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

02/20/26

Analysts Offer Insights on Healthcare Companies: Butterfly Network (NYSE: BFLY), UnitedHealth (NYSE: UNH) and Travere Therapeutics (NASDAQ: TVTX)

Yigal Nochomovitz

Citi

$48

Buy

57.95%

Upside

Reiterated

02/20/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bicara Therapeutics Inc. (NASDAQ: BCAX), Accendra Health (NYSE: ACH) and Travere Therapeutics (NASDAQ: TVTX)

Vamil Divan

Guggenheim

$49

Buy

61.24%

Upside

Reiterated

02/11/26

Guggenheim Keeps Their Buy Rating on Travere Therapeutics (TVTX)

Allison Bratzel

Piper Sandler

$35→$38

Hold

25.04%

Upside

Reiterated

02/06/26

Travere Therapeutics price target raised to $38 from $35 at Piper SandlerTravere Therapeutics price target raised to $38 from $35 at Piper Sandler

Joseph Schwartz

Leerink Partners

―

Buy

―

Reiterated

01/13/26

Leerink says Travere's Filspari PDUFA extension removes worst case scenario Leerink says Travere's Filspari PDUFA extension removes worst case scenario

Gavin Clark-Gartner

Evercore ISI

$42

Buy

38.20%

Upside

Reiterated

01/13/26

Evercore ISI Remains a Buy on Travere Therapeutics (TVTX)

Mohit Bansal

Wells Fargo

$40

Buy

31.62%

Upside

Reiterated

01/13/26

Wells Fargo Remains a Buy on Travere Therapeutics (TVTX)

Maury Raycroft

Jefferies

$35

Buy

15.17%

Upside

Reiterated

09/10/25

AdCom cancellation 'clear positive' for Travere Therapeutics, says JefferiesAdCom cancellation 'clear positive' for Travere Therapeutics, says Jefferies

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Travere Therapeutics

3 Months

xxx

Success Rate

10/15 ratings generated profit

Average Return

+24.69%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +24.69% per trade.

1 Year

Tyler Van BurenTD Cowen

Success Rate

14/16 ratings generated profit

Average Return

+56.27%

a rating ―

Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +56.27% per trade.

2 Years

xxx

Success Rate

15/16 ratings generated profit

Average Return

+95.05%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 93.75% of your transactions generating a profit, with an average return of +95.05% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TVTX Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TVTX has received 29 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. TVTX average Analyst price target in the past 3 months is 42.73.

Each month's total comprises the sum of three months' worth of ratings.

TVTX Financial Forecast

TVTX Earnings Forecast

Next quarter’s earnings estimate for TVTX is -$0.23 with a range of -$0.61 to $0.15. The previous quarter’s EPS was $0.03. TVTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year TVTX has Performed in-line its overall industry.

TVTX Sales Forecast

Next quarter’s sales forecast for TVTX is $137.14M with a range of $110.51M to $162.00M. The previous quarter’s sales results were $129.69M. TVTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year TVTX has Performed in-line its overall industry.

TVTX Stock Forecast FAQ

What is TVTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Travere Therapeutics’s 12-month average price target is 42.73.

What is TVTX’s upside potential, based on the analysts’ average price target?

Travere Therapeutics has 40.60% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TVTX a Buy, Sell or Hold?

Travere Therapeutics has a consensus rating of Strong Buy which is based on 12 buy ratings, 2 hold ratings and 0 sell ratings.

What is Travere Therapeutics’s price target?

The average price target for Travere Therapeutics is 42.73. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $49.00 ,the lowest forecast is $31.00. The average price target represents 40.60% Increase from the current price of $30.39.

What do analysts say about Travere Therapeutics?

Travere Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of TVTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Travere Therapeutics (TVTX) Stock Forecast & Price Target

TVTX Analyst Ratings

TVTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Travere Therapeutics

TVTX Analyst Recommendation Trends

TVTX Financial Forecast

TVTX Earnings Forecast

TVTX Sales Forecast

TVTX Stock Forecast FAQ

Detailed List of Analyst Forecasts